SAN DIEGO--(BUSINESS WIRE )--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase its expanded global portfolio of real-time continuous glucose monitoring (CGM) systems at the 82nd Scientific Sessions of the American Diabetes Association (ADA) conference held in New Orleans and virtually, June 3-7, 2022. Featured research and data presentations headlining the conference will also reiterate the use of Dexcom CGM as central to optimal diabetes management.
“Once again, we are kicking off another annual diabetes conference that will showcase real-time CGM as the standard of care in diabetes management with Dexcom CGM leading the way in accuracy, performance and adherence,” said Kevin Sayer, chairman, president and CEO of Dexcom. “It is an exciting time for Dexcom as we introduce our expanded CGM portfolio and build on our industry-leading connectivity. With the launch of Insulet’s Omnipod 5 automated insulin delivery system, we are excited to now support the leading tubeless pump technology in addition to what we believe to be the leading tethered pump technology in Tandem Control-IQ.”
Key posters and research to be presented at ADA include:
The Dexcom CGM Product Portfolio and Proven Outcomes:
Outcomes from Automated Insulin Delivery Systems Powered by Dexcom CGM:
Evidence and Outcomes for Dexcom CGM Use in Additional Care Settings:
For more information about the 82nd Scientific Sessions of the American Diabetes Association and to register to attend the conference, visit professional.diabetes.org/scientific-sessions.
DexCom, Inc. empowers people to take control of diabetes through innovative real-time continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and in select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
1Dexcom G7 is 510(k) pending. Not available for sale or distribution in the United States. Dexcom ONE is not for sale or distribution in the United States.
2Dexcom G7, Dexcom G6 and Dexcom ONE User Guide.
3Visser MM, et al. Lancet 2021;397(10291):2275-83.
© 2022 Dexcom, Inc. Dexcom, Dexcom ONE, Dexcom G6 and Dexcom G7 are registered trademarks of DexCom, Inc. in the U.S., and may be registered in other countries. All rights reserved.
Media Contact James McIntosh 619-884-2118 james.mcintosh@dexcom.com
Investor Contact Sean Christensen 858-203-6657 sean.christensen@dexcom.com
DEXCOM TO SHOWCASE EXPANDED CGM PORTFOLIO AND INDUSTRY-LEADING CONNECTIVITY AT 82ND SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION
Media Contact James McIntosh 619-884-2118 james.mcintosh@dexcom.com
Investor Contact Sean Christensen 858-203-6657 sean.christensen@dexcom.com